Printer Friendly

TELIOS PHARMACEUTICALS SIGNS AN AGREEMENT WITH LILLY TO DEVELOP NOVEL OSTEOPOROSIS THERAPEUTICS

 SAN DIEGO, Jan. 11 /PRNewswire/ -- Telios Pharmaceuticals Inc. (NASDAQ: TLIO) today announced that it has entered into a research agreement with Eli Lilly and Company to develop, test and market integrin-specific compounds for the prevention and/or treatment of osteoporosis. The project will focus on designing molecules to inhibit and control receptors on certain cells that attach to and weaken bone. Osteoporosis is a serious condition which leads to the debilitating bone fractures common in postmenopausal women and elderly men.
 Under the terms of the agreement, Lilly will acquire 500,000 shares of Telios common stock for $4 million and will provide at least $1.5 million per year in research funding to Telios for up to four years. Telios will also receive additional license fees upon achievement of clinical and regulatory milestones. Lilly will be responsible for toxicology studies and clinical development and will have exclusive worldwide marketing and sales rights. Telios will have manufacturing rights and will also receive royalties on product sales.
 Telios has focused on designing peptides containing the cell adhesion sequence, arginine-glycine-aspartic acid (RGD), with different conformations to target selected integrin receptors on cells. Michael D. Pierschbacher, Ph.D., senior vice president, scientific director, and co-inventor of the RGD peptide technology stated, "We look forward to combining our research expertise in peptide synthesis and design with Lilly's strong capabilities in bone biology and pharmaceutical development."
 Telios is developing a new class of therapeutic products based upon research into the role of the extracellular matrix in disease and tissue repair. The company is applying its proprietary technology to develop products for the treatment of severe and chronic dermal wounds, ophthalmic wounds, fibrotic diseases, cardiovascular diseases and osteoporosis.
 -0- 1/11/93
 /CONTACT: Audrey D. Keane, director of corporate development of Telios Pharmaceuticals, 619-622-2615/
 (TLIO)


CO: Telios Pharmaceuticals Inc.; Eli Lilly and Company ST: California IN: MTC SU: CON

JL -- SD004 -- 3544 01/11/93 12:23 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 11, 1993
Words:321
Previous Article:COMMERCE BANCORP REPORTS 1992 EARNINGS
Next Article:SYMANTEC SHIPS TWO NEW PROJECT MANAGEMENT PRODUCTS; MAKES IT EASY TO CREATE SCHEDULES FOR TIME LINE, ON TARGET & MICROSOFT PROJECT
Topics:


Related Articles
TELIOS PHARMACEUTICALS INC. SELLS 2.5 MILLION SHARES OF COMMON STOCK IN INITIAL PUBLIC OFFERING
PFIZER AND PROCTOR & GAMBLE SIGN AGREEMENT ON OSTEOPOROSIS TREATMENT DRUG
TELIOS SIGNS AGREEMENT WITH ST. JUDE MEDICAL INC. FOR BIOCOMPATIBLE COATING
TELIOS ANNOUNCES SBIR GRANT FOR DECORIN
NPS PHARMACEUTICALS AND SMITHKLINE BEECHAM TO COLLABORATE ON OSTEOPOROSIS DRUG RESEARCH
ELI LILLY & CO. TERMINATES FUNDING OF RESEARCH AGREEMENT WITH TELIOS PHARMACEUTICALS
NPS Announces Extension Of Osteoporosis Agreement With SmithKline Beecham
Scios and Lilly Enter Into Agreement for Alzheimer's Disease Research
Millennium Pharmaceuticals, Inc. Announces Extension of Collaboration With Eli Lilly and Company
Scios Joins Genetic Institute's DiscoverEase(R) Program

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters